Poxviridae Infections - Pipeline Review, H2 2016

  • ID: 3895082
  • Report
  • 96 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • BioFactura, Inc.
  • CEL-SCI Corporation
  • Chimerix, Inc.
  • CJ HealthCare Corp.
  • EpiVax, Inc.
  • MORE
Poxviridae Infections - Pipeline Review, H2 2016

Summary

‘Poxviridae Infections - Pipeline Review, H2 2016’, provides an overview of the Poxviridae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poxviridae Infections , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poxviridae Infections and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Poxviridae Infections
- The report reviews pipeline therapeutics for Poxviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Poxviridae Infections therapeutics and enlists all their major and minor projects
- The report assesses Poxviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Poxviridae Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Poxviridae Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poxviridae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • BioFactura, Inc.
  • CEL-SCI Corporation
  • Chimerix, Inc.
  • CJ HealthCare Corp.
  • EpiVax, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Poxviridae Infections Overview

Therapeutics Development

Pipeline Products for Poxviridae Infections - Overview

Pipeline Products for Poxviridae Infections - Comparative Analysis

Poxviridae Infections - Therapeutics under Development by Companies

Poxviridae Infections - Therapeutics under Investigation by Universities/Institutes

Poxviridae Infections - Pipeline Products Glance

Late Stage Products

Early Stage Products

Poxviridae Infections - Products under Development by Companies

Poxviridae Infections - Products under Investigation by Universities/Institutes

Poxviridae Infections - Companies Involved in Therapeutics Development

Bavarian Nordic A/S

BioFactura, Inc.

CEL-SCI Corporation

Chimerix, Inc.

China Biologic Products, Inc.

CJ HealthCare Corp.

EpiVax, Inc.

N & N Pharmaceuticals Inc.

SIGA Technologies, Inc.

Takeda Pharmaceutical Company Limited

Tonix Pharmaceuticals Holding Corp.

Verrica Pharmaceuticals Inc.

Poxviridae Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(plague + small pox) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

24a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BA-368 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brincidofovir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-40011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Smallpox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Molluscum Contagiosum - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

small pox vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smallpox vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smallpox vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tecovirimat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varicella hyperimmune globulins - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIR-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIR-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poxviridae Infections - Dormant Projects

Poxviridae Infections - Discontinued Products

Poxviridae Infections - Product Development Milestones

Featured News & Press Releases

Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government

Apr 25, 2016: SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat

Mar 17, 2016: SIGA Commences Clinical Study for Intravenous (IV) Formulation of TPOXX

Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral

Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral

Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox

Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene

Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox

Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox

Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million

May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine

Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery

Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million

Dec 23, 2014: Chimerix Provides Recap of 2014 Events

Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Poxviridae Infections, H2 2016

Number of Products under Development for Poxviridae Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Poxviridae Infections - Pipeline by Bavarian Nordic A/S, H2 2016

Poxviridae Infections - Pipeline by BioFactura, Inc., H2 2016

Poxviridae Infections - Pipeline by CEL-SCI Corporation, H2 2016

Poxviridae Infections - Pipeline by Chimerix, Inc., H2 2016

Poxviridae Infections - Pipeline by China Biologic Products, Inc., H2 2016

Poxviridae Infections - Pipeline by CJ HealthCare Corp., H2 2016

Poxviridae Infections - Pipeline by EpiVax, Inc., H2 2016

Poxviridae Infections - Pipeline by N & N Pharmaceuticals Inc., H2 2016

Poxviridae Infections - Pipeline by SIGA Technologies, Inc., H2 2016

Poxviridae Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Poxviridae Infections - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016

Poxviridae Infections - Pipeline by Verrica Pharmaceuticals Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Poxviridae Infections - Dormant Projects, H2 2016

Poxviridae Infections - Dormant Projects (Contd..1), H2 2016

Poxviridae Infections - Dormant Projects (Contd..2), H2 2016

Poxviridae Infections - Discontinued Products, H2 2016 86List of Figures

Number of Products under Development for Poxviridae Infections, H2 2016

Number of Products under Development for Poxviridae Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • BioFactura, Inc.
  • CEL-SCI Corporation
  • Chimerix, Inc.
  • CJ HealthCare Corp.
  • EpiVax, Inc.
  • MORE
According to our recently published report 'Poxviridae Infections – Pipeline Review, H2 2016'; Poxviridae Infections pipeline therapeutics constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Poxviridae Infections Poxvirus infections are a group of infections caused by Poxviruses, members of the Poxviridae family. Symptoms include skin eruptions, fever, rash, muscle pain, headache, body aches and vomiting. Treatment includes antiviral medications.

The report 'Poxviridae Infections – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Poxviridae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Poxviridae Infections and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 3, 12 and 6 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Bavarian Nordic A/S
BioFactura, Inc.
CEL-SCI Corporation
Chimerix, Inc.
China Biologic Products, Inc.
CJ HealthCare Corp.
EpiVax, Inc.
N & N Pharmaceuticals Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Verrica Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll